HBsAg水平与抗乙型肝炎病毒药物治疗远期效果相关性分析

目的:通过观察HBeAg/HBeAb血清转换率与HBsAg定量的关系,探讨抗病毒治疗的远期疗效预测指标。方法:慢性乙型肝炎患者66例随机分为2组,即干扰素组、拉米夫定组。在治疗前后不同时间分别检测血清HBVDNA、HBsAg、HBeAg/HBeAb。根据治疗前HBsAg水平分级,计算治疗3个月时HBsAg抑制率和HBeAg/HBeAb血清转换率。结果:HBsAg初始水平低于100ng·L-1时,干扰素组HBeAg/HBeAb血清转换率显著提高,P<0.05。治疗3个月时,HBsAg抑制率超过50%,HBeAg/HBeAb血清转换率为47%。结论:HBsAg初始水平或治疗3个月后下降幅度是治疗慢性乙型病毒性肝炎疗效的预测指标。

Analysis on the Relationship of the Quantity of HBsAg with Long-term Efficacy of Anti-hepatitis B Virus Agent

OBJECTIVE：To observe the relationship of the quantity of HBsAg with seroconversion ratio of HBeAg/HBeAb and to search predictors of lone-term efficacy of antivirus therapy.METHODS：66 patients with chronic hepatitis B（CHB） were randomly divided into lamivudine group and IFN-α2b group.The level of HBV DNA and the quantities of HBsAg and HBeAg/HBeAb in serum were detected.According to the classification of HBsAg,inhibition rate of HBsAg after 3 months of treatment and seroconversion ratio of HBeAg/HBeAb at the end of treatment were calculated.RESULTS：When the quantities of HBsAg was lower than 100 ng·L-1,seroconversion ratio of HBeAg/HBeAb in IFN-α2b group was improved significantly.Inhibition rate of HBsAg was more than 50% after 3 months of treatment and seroconversion ratio of HBeAg/HBeAb was 47% at the end of treatment.CONCLUSION：Initial level of HBsAg and decreasing range after 3 months of treatment are efficacy predictors of CHB therapy.